8br7: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Discovery of IRAK4 Inhibitors BAY1834845 and BAY1830839== | |||
<StructureSection load='8br7' size='340' side='right'caption='[[8br7]], [[Resolution|resolution]] 2.12Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[8br7]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8BR7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8BR7 FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.119Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=R6R:3-nitro-~{N}-[2-[2-oxidanylidene-2-[4-(phenylcarbonyl)piperazin-1-yl]ethyl]indazol-5-yl]benzamide'>R6R</scene>, <scene name='pdbligand=SEP:PHOSPHOSERINE'>SEP</scene>, <scene name='pdbligand=TPO:PHOSPHOTHREONINE'>TPO</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8br7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8br7 OCA], [https://pdbe.org/8br7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8br7 RCSB], [https://www.ebi.ac.uk/pdbsum/8br7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8br7 ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in innate inflammatory processes. Here, we describe the discovery of two clinical candidate IRAK4 inhibitors, BAY1834845 (zabedosertib) and BAY1830839, starting from a high-throughput screening hit derived from Bayer's compound library. By exploiting binding site features distinct to IRAK4 using an in-house docking model, liabilities of the original hit could surprisingly be overcome to confer both candidates with a unique combination of good potency and selectivity. Favorable DMPK profiles and activity in animal inflammation models led to the selection of these two compounds for clinical development in patients. | |||
Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839.,Bothe U, Gunther J, Nubbemeyer R, Siebeneicher H, Ring S, Bomer U, Peters M, Rausch A, Denner K, Himmel H, Sutter A, Terebesi I, Lange M, Wengner AM, Guimond N, Thaler T, Platzek J, Eberspacher U, Schafer M, Steuber H, Zollner TM, Steinmeyer A, Schmidt N J Med Chem. 2024 Jan 25;67(2):1225-1242. doi: 10.1021/acs.jmedchem.3c01714. Epub , 2024 Jan 16. PMID:38228402<ref>PMID:38228402</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: | <div class="pdbe-citations 8br7" style="background-color:#fffaf0;"></div> | ||
[[Category: | == References == | ||
[[Category: | <references/> | ||
[[Category: | __TOC__ | ||
[[Category: | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: | [[Category: Large Structures]] | ||
[[Category: | [[Category: Boemer U]] | ||
[[Category: | [[Category: Bothe U]] | ||
[[Category: | [[Category: Denner K]] | ||
[[Category: | [[Category: Eberspaecher U]] | ||
[[Category: | [[Category: Guimond N]] | ||
[[Category: Ring | [[Category: Gunther J]] | ||
[[Category: | [[Category: Himmel H]] | ||
[[Category: | [[Category: Lange M]] | ||
[[Category: | [[Category: Nubbemeyer R]] | ||
[[Category: Steuber | [[Category: Peters M]] | ||
[[Category: | [[Category: Platzek J]] | ||
[[Category: | [[Category: Ring S]] | ||
[[Category: | [[Category: Schafer M]] | ||
[[Category: | [[Category: Schmidt N]] | ||
[[Category: | [[Category: Siebeneicher H]] | ||
[[Category: Steinmeyer A]] | |||
[[Category: Steuber H]] | |||
[[Category: Sutter A]] | |||
[[Category: Terebesi I]] | |||
[[Category: Thaler T]] | |||
[[Category: Wenger AM]] | |||
[[Category: Zollner TM]] | |||
Latest revision as of 09:46, 9 October 2024
Discovery of IRAK4 Inhibitors BAY1834845 and BAY1830839
| ||||||||||||
